Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: influence of ruxolitinib, interferon-α2, or combination treatment

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Addressing the room for improvement in management of acute promyelocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognostic role of genetic polymorphisms of the interleukin-6 signaling pathway in patients with severe heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Thyroid peroxidase antibodies and prospective live birth rate: A cohort study of women with recurrent pregnancy loss

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Expanding the citrullinome of synovial fibrinogen from rheumatoid arthritis patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Erythrocytes restrict microvesicle-induced production of reactive oxygen species by polymorphonuclear leukocytes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Given a proposed role for PD-L1+ and IL-10-producing B-cell subsets in promoting certain cancers, we sought to characterize the frequency and phenotype of B cells in patients with chronic myeloproliferative neoplasms (MPNs) and the influence of ruxolitinib and interferon-α2 therapy.

METHODS: We analyzed B-cell frequencies and phenotype in patients with MPNs (n=107), before and during treatment with ruxolitinib (n=29), interferon-α2 (n=21), or the two drugs in combination (COMBI) (n=42) and healthy donors (HDs) (n=52) using flow cytometry.

RESULTS: Myelofibrosis patients had lower lymphocyte counts and proportions of B cells than patients with essential thrombocytosis or polycythemia vera and HDs. The B-cell count correlated inversely with JAK2-V617F allele burden and spleen size and increased after ruxolitinib or COMBI treatment. The proportions of PD-L1+ B cells and PD-1+ B cells were significantly higher in patients with myelofibrosis or polycythemia vera than in HDs and decreased during ruxolitinib and COMBI treatment. The proportions of TNF-α+ and IL-6+ B cells were elevated in myelofibrosis patients. The proportion of IL-6+ B cells decreased, and the proportion of IL-10+ B cells increased during ruxolitinib treatment.

CONCLUSION: B-cell frequency and phenotype were altered in MPN patients. Ruxolitinib therapy had marked effects on both frequency and phenotype. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalEuropean Journal of Haematology
Volume103
Issue number4
Pages (from-to)351-361
ISSN0902-4441
DOIs
Publication statusPublished - Oct 2019

Bibliographical note

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

ID: 57728420